Pharmanovia Acquires Global Central Nervous System (CNS) Portfolio From Sanofi
PRESS RELEASE – FOR TRADE, BUSINESS AND MEDICAL MEDIA ONLY
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230918003077/en/
James Burt, CEO, Pharmanovia (Photo: Business Wire)
Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises, extends and expands the lifecycle of established medicines, has today announced the expansion of its neurology portfolio with the acquisition of 11 central nervous system (CNS) brands from global healthcare company, Sanofi.
The brands span four therapy areas of ongoing unmet need associated with CNS disorders - psycholeptic, anxiolytic, anti-epileptic and anti-psychotic.
Clobazam is from a class of drug called benzodiazepines and can be used to treat anxiety, with or without insomnia or certain psychiatric conditions, in certain patients.1 The acquired brands include Frisium®, Sentil®, Urbanyl®, Urbanil®, Urbanol®, Urbadan®, Noiafren® and Castilium®*. Frisium® may also be used as adjunctive therapy in epilepsy.1
Phenobarbital (brand: Gardenal®*) is used as an anti-convulsant to treat all forms of epilepsy except absence seizures.2
Cyamemazine (brand: Tercian®*†) is used to treat certain types of psychotic conditions, anxiety in patients where other treatments have failed and also some types of depression in combination with another anti-depressant.3
Prochlorperazine (brand: Stemetil®*) is used to treat vertigo, and nausea and vomiting due to various causes. It may also be used for other conditions such as schizophrenia, acute mania and as an adjunct to the short-term management of anxiety.4,5
Dr James Burt, Pharmanovia CEO, commented: “Sanofi’s decision to divest this established CNS portfolio, with leading brands such as Frisium® and Gardenal®, to Pharmanovia is recognition of our neurology expertise, our capabilities in lifecycle management and reputation of being a trusted divestment partner. We’re excited to use this knowledge and our global platform to ensure these important medicines not only continue to be available to the millions of patients who need them, but - through our lifecycle management - continue to evolve to meet patient needs.”
“Through this acquisition, we are not only building depth in geography, but we’re also bringing in products that have a clear synergy with our existing portfolio and the core sub-therapy focuses of mental health and epilepsy, where there continues to be significant unmet need.”
Notes to editors
*Not all indications are approved in every market. For local indications it is advised to check the local approved label. †Tercian® is only available in France.
Pharmanovia is a global lifecycle management healthcare company. Our purpose is to make medicines fit for tomorrow, to improve the lives of patients globally.
We do this by enhancing established medicines by rediscovering, repurposing or re-engineering iconic brands to improve patient outcomes and experiences both through in-house development and strategic partnerships.
Our diverse and growing team operate in over 160 countries across the globe, delivering high-quality solutions, ethically and sustainably, across our four core therapeutic areas – Endocrinology, Neurology, Cardiovascular and Oncology.
For more information about Pharmanovia, please visit www.pharmanovia.com
Sanofi is an innovative global healthcare company, driven by one purpose: to chase the miracles of science to improve people’s lives. Its team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. Sanofi provides potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the centre of its ambitions.
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY.
1 - Frisium Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/1574 –last accessed 11.9.2023
2 - Phenobarbital Sodium Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3604/smpc#gref- last accessed 11.9.2023
3 - Terican Summary of Product Characteristics, https://base-donnees-publique.medicaments.gouv.fr/affichageDoc.php?specid=66615713&typedoc=R – last accessed 11.9.2023
4 - Stemetil Injection Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/3735/smpc#about-medicine- last accessed 11.9.2023
5 - Stemetil Tablets Summary of Product Characteristics, https://www.medicines.org.uk/emc/product/99/smpc#about-medicine-last accessed 11.9.2023
COR2023PR00207 – Date of Preparation – 14.9.2023
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Monument Re Limited Announces Key Staffing Changes4.10.2023 18:00:00 CEST | Press release
Monument Re Limited (“Monument Re”) announced today that Manfred Maske has stepped down from his role as Group CEO effective from 19th September 2023. Jonathan Yates, Chairman of Monument Re, stated that “Manfred joined Monument Re Group in February 2017, when the company was a relatively new venture. Over 6 years of dedicated service, Manfred has played an integral role in creating the market leading business that it is today. Together with the Senior Leadership Team, I would like to thank Manfred for his leadership, commitment, dedication and invaluable contribution to the creation of the Monument Re Group. We wish Manfred the best of success in his future endeavours”. Monument further announced that Carlo Elsinghorst has been appointed as Group CEO. Carlo joined Monument in 2020 as CEO Ireland and was appointed Group CFO in April 2022. During his time at Monument, Carlo successfully led the Irish team through a series of domestic acquisitions and the growing maturity of the organisa
Linksys Announces Global Expansion with Additional Offices4.10.2023 18:00:00 CEST | Press release
Linksys, an iconic Home and Small Office connectivity company, announces plans to expand globally with a development location in Taipei, Taiwan, and a new Sales and Marketing location in Amstelveen, Netherlands. Linksys is reasserting itself in both the Residential Retail and Residential Service Provider markets, which has driven the need to expand beyond its Irvine, California headquarters of 35+ years. The new offices will be near the major technology hubs of both countries and are also in close proximity to several universities that offer the talent necessary for Linksys to drive its growth targets over the next five years and beyond. “It’s a big world out there, and it is long overdue that Linksys push out beyond our Irvine, California headquarters and create anchor offices in other regions where we expect to grow in the coming years,” said Linksys CEO Jonathan Bettino. “Although we work from home quite a lot, having an office to go to a couple of times a week helps build teamwork
FPT Software’s MaaZ Wins AutoTech Breakthrough “Overall Connected Solution of the Year”4.10.2023 16:30:00 CEST | Press release
FPT Software’s MaaZ was recently awarded the “Overall Connected Solution of the Year” at the fourth annual AutoTech Breakthrough Awards in first-time nomination. This recognition underscores the IT services provider's robust automotive tech competency in the software-defined vehicle era. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004432860/en/ (Graphic: Business Wire) Conducted by Tech Breakthrough, the annual AutoTech Breakthrough Awards program is the industry’s most comprehensive analysis and evaluation to recognise top companies, technologies and products in today's global automotive and transportation technology markets. Surpassing more than 1,600 nominations from over 15 countries, FPT Software's MaaZ is the only solution named the “Overall Connected Solution of the Year.” Launched in 2022, MaaZ is a comprehensive connected car solution aiming to assist worldwide automotive suppliers and car OEMs to tackle the c
Xsolla Powers Web Shop Launches for 40 of the Top 100 Mobile Games4.10.2023 16:00:00 CEST | Press release
Xsolla, a global video game commerce company, shares insights that 40 of the top 100 mobile games have launched their Web Shop using Xsolla's solution. These insights offer a glimpse into the increasing trend of multiplatform operations in the mobile gaming industry for 2023 and entering 2024. Based on Xsolla’s research and analysis, they have assisted 151 games in launching Web Shops this year. This achievement reflects the mobile gaming landscape's transformation, with a move towards cross-platform integration. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004310876/en/ Xsolla Web Shop (Graphic: Business Wire) "With the support of Xsolla, 80.lv is shedding light on the growing need for a connective platform in the gaming industry," said Kirill Tokarev, CEO of 80.lv. "This concept aims to provide equal opportunities for gaming and porting studios, particularly those with limited internal capacity, by connecting them wit
New Research: A Quarter of US Network Engineers Are Set to Retire in Five Years4.10.2023 15:00:00 CEST | Press release
According to new research released today by Opengear, a Digi International company (NASDAQ, DGII, www.digi.com) and provider of secure and SmartOut of Bandmanagement solutions, 86% of U.S.-based CIOs surveyed expect at least 25% of their network engineers to retire in the next five years. The networking industry is facing a skills shortage as engineers continue retiring. Almost every CIO (95%) surveyed said that a shortfall in engineers has led to an inability to manage networks, and 91% of U.S. engineers and 81% of global engineers surveyed agree with this. Additionally, 79% of U.S. CIOs state that they are now struggling to meet user or customer expectations in today’s economic environment. The Opengear study surveyed 502 CIOs and 510 network engineers across the U.S., U.K., France, Germany and Australia. It shows that 98% of U.S. engineers surveyed have been forced to achieve more with fewer resources over the past three months, which is even higher than those in the U.K. (88%) and